In its Q2 2026 investor letter, Alger Small Cap Focus Fund highlighted Forte Biosciences, Inc. (NASDAQ:FBRX). Forte Biosciences, Inc. (NASDAQ:FBRX), a US-based clinical-stage biopharmaceutical company, detracted from the Fund's performance during the quarter. On July 20, 2026, Forte Biosciences, Inc. (NASDAQ:FBRX) closed at $47.49 per share, reflecting a market capitalization of $972.54 million. Forte Biosciences, Inc. (NASDAQ:FBRX) posted a one-month return of 161.65%, while its shares gained 355.32% over the past 52 weeks. Alger Small Cap Focus Fund stated the following regarding Forte Biosciences, Inc. (NASDAQ:FBRX) in its Q2 2026 investor update: